Agency information collection activities: owned; availability for licensing,

[Federal Register: July 14, 1999 (Volume 64, Number 134)]

[Notices]

[Page 37989]

From the Federal Register Online via GPO Access [wais.access.gpo.gov]

[DOCID:fr14jy99-123]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Invention; Availability for Licensing: ``Immunotoxin Containing a Disulfide-Stabilized Antibody Fragment Joined to a Pseudomonas Exotoxin that does not Require Proteolytic Activation''

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally funded research and development.

ADDRESSES: Licensing information and a copy of the U.S. patent application referenced below may be obtained by contacting J.R. Dixon, Ph.D., at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852- 3804 (telephone 301/496-7056 ext 206; fax 301/402-0220; E-Mail: jd212g@NIH.GOV). A signed Confidential Disclosure Agreement is required to receive a copy of any patent application.

SUPPLEMENTARY INFORMATION:

Invention Title: ``Immunotoxin Containing a Disulfide-Stabilized Antibody Fragment Joined to a Pseudomonas Exotoxin that does not Require Proteolytic Activation''

Inventors: Drs. Ira H. Pastan (NCI), and Chin-Tsun Kuan (NCI)

DHHS Ref. No. E-163-93/1 & 2 & 3--USPA SN: 08/809,668--FiledAugust 21, 1997, [=60/005,388--Filed: October 13, 1995, & PCT/US96/16327/WO 97/13529--Filed: October 11, 1996]

Licensing Contract: J.R. Dixon, Ph.D., (301)-496-7056 Ext. 206; E- Mail: jd212g@NIH.GOV

Immunotoxins were initially produced by chemically coupling antibodies to toxins to form chimeric molecules. In these molecules, the antibody portion mediates selective binding to target cells, while the toxin portion mediates translocation into the cytosol and subsequent cell killing. Several toxins have been used to make immunotoxins including ricin A chain, blocked ricin, saporin, pokeweed antiviral protein, diphtheria toxin, and Pseudomonas Exotoxin (``PE'').

The technology disclosed in the above mentioned patent application relates to the production and use of Pseudomonas-derived immunotoxins modified to increase their toxicity and potency and therapeutic agents. In particular, the immunotoxins of this invention includes a disulfide- stabilized (``ds'') target-binding agent, such as the variable region of an antibody molecule, and a Pseudomonas Exotoxin that does not require proteolytic activation for cytotoxic activity. Specifically, the invention provides for immunotoxins comprising a Pseudomonas Exotoxin that does not require proteolytic activation for cytotoxic activity attached to an Fv antibody fragment having a variable heavy chain region bound through at least one disulfide bond to a variable light chain region. The combination of a ``disulfide-stabilized'' binding agent fused to a PE that does not require proteolytic activation and provides an immunotoxin having surprising cytotoxic activity.

The above mentioned Invention is available, including any available foreign intellectual property rights, for licensing.

Dated: July 2, 1999. Jack Spiegel, Director, Division of Technology Development & Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 99-17928Filed7-13-99; 8:45 am]

BILLING CODE 4140-01-M